PASG

Conviction 20HealthcareScan · Mon, Aug 10, 2026

PASG$4.42+0.34%

ResistanceSupportVol 14Insider buy

Vol MA14 19.26K

May 11May 28Jun 16Jul 6Jul 23Aug 10

Passage BIO, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.passagebio.com ↗

Price4.42

Change+0.34%

Gap+1.36%

Rel volume0.11×

Avg volume30.43K

Avg $ vol145.2K

SMA 204.66

SMA 505.04

SMA 2007.89

Price vs 50-12.33%

Price vs 200-44.04%

MA stackbearish

50/200 cross—

Supertrenddown · 5.20

RSI (14)40

MACD hist-0.00

MACD crossbear · 1d

Stoch %K / %D13 / 11

ADX (14)38

+DI / −DI10 / 25

RSI divergence—

MACD divergence—

ATR %+6.62%

ADR %5.34%

52w high19.85

52w low4.08

From 52w high-77.76%

Above 52w low+8.21%

New 52w highNo

SqueezeOn · 13d

Bollinger width17.31%

%B0.20

Donchian pos21.71%

Donchian high5.01

Donchian low4.25

AVWAP (52w high)7.07

vs AVWAP high-37.55%

AVWAP (52w low)4.53

vs AVWAP low-2.64%

OBV trendFlat

Chaikin MF (20)0.07

Today vs 20d0.11×

Avg vol (14d)19.26K

Avg vol (20d)30.43K

Avg $ vol (20d)145.2K

Market cap14.21M

RS 3m (vs SPY)+2.15%

RS 6m (vs SPY)-65.82%

RS line new highNo

Trend template1/8

Technical rank10.3

1 week-1.67%

1 month-3.39%

3 months+4.87%

6 months-53.58%

1 year-21.31%

YTD-62.23%

P/E-0.31

P/B3.19

P/S—

P/FCF-0.45

EPS-14.35

Div yield—

ROE—

ROA-180.82%

Debt/Eq—

Current1.22

EV/EBITDA0.20

Gross margin—

Net margin—

Rev growth—

EPS growth29.71%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value-9.95M

Revenue—

Net income-7.82M

Gross profit—

Free cash flow-31.54M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out3.21M

Employees24

ListedFri, Feb 28, 2020

Free float2.84M

Float %88.7%

Short interest124.63K

Days to cover2.6d

Short volume54.1%

Squeeze score31 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction20 / 100

Pattern quality—

Tech rank10.3 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance5.68

Support3.77

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in PASG

All disclosures →

No recent disclosed trades by Congress in PASG. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in PASG · 7 buys

Insider	Side	Shares	Value	Traded	Filed
Lynx1 Capital Management LP 10% owner · Common stock, $0.0001 par value per share ("Common Stock") · 2026-06-25	Buy	50.05K	$206K	2026-06-25	2026-06-29
GOWEN MAXINE Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21
Porter Derrell Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21
Kassberg Thomas Richard Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21
Countouriotis Athena Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21
Sondhi Dolan Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21
Kapadia Sandip Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21

SEC filings

EDGAR filings in PASG · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.